Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov-Dec;15(6):241-247.
doi: 10.4103/ijt.ijt_145_22. Epub 2024 Oct 7.

TH07 - A New Novel Topical Treatment for Androgenic Alopecia

Houfar Sekhavat  1 , Peter Ford  2 , Anik Lepage  3 , Ariana Nateghi  4 , Sara Bar Yehuda  1 , Marianne Bourgeois  1
Affiliations

TH07 - A New Novel Topical Treatment for Androgenic Alopecia

Houfar Sekhavat et al. Int J Trichology. 2023 Nov-Dec.

Abstract

Objectives: Androgenic alopecia (AGA) is common among men. Currently, topical minoxidil and oral finasteride are approved by the FDA for the treatment of AGA. Unfortunately, neither of them is completely effective and systemic adverse events have been reported after finasteride administration. Triple Hair Inc. has developed a new topical treatment regimen using a combination of finasteride, latanoprost and minoxidil - TH07. Each of the compounds was effective and safe as a topical treatment in animal models and clinical studies of AGA. The aim of this proof-of-concept study was to evaluate the effectiveness of the TH07 in comparison to the 3 drugs as monotherapy on hair growth in men with AGA.

Methods: Patients with light to moderate AGA were randomized to be treated topically, once daily, for 6 months with TH07, 0.1% finasteride, 0.03% latanoprost, or 5% minoxidil. Data of investigators' assessment based on pictures, as well as patients' self-assessment and satisfaction, were collected.

Results: A moderate hair re-growth in the majority of the participant treated with TH07 in comparison to the retreatment with its active components administered as monotherapy was reported by the investigators. Most of the patients treated with TH07 were satisfied with their hair appearance in comparison to the other treatments. No systemic adverse events were reported and the TH07 was well tolerated.

Conclusions: The data of the current study demonstrated that the topical administration of TH07 resulted in an improved efficacy in the treatment of the AGA compared to treatment with each of the ingredients administered separately.

Keywords: Androgenic alopecia; combination; finasteride; latanoprost; minoxidil; topical treatment.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
A representative picture of 2 patients, before and after the treatment with TH07
Figure 2
Figure 2
Rational for a combined therapy in AGA. AGA: androgenetic alopecia
See this image and copyright information in PMC

References

    1. Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010;11:1295–304. - PubMed
    1. Bergfeld WF. Androgenetic alopecia: An autosomal dominant disorder. Am J Med. 1995;98:95S–8S. - PubMed
    1. Norwood OT. Male pattern baldness: Classification and incidence. South Med J. 1975;68:1359–65. - PubMed
    1. Ishino A, Takahashi T, Suzuki J, Nakazawa Y, Iwabuchi T, Tajima M. Contribution of hair density and hair diameter to the appearance and progression of androgenetic alopecia in Japanese men. Br J Dermatol. 2014;171:1052–9. - PubMed
    1. Tsai MJ, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994;63:451–86. - PubMed

LinkOut - more resources